The evidence for using conjugate vaccines to protect HIV-infected children against pneumococcal disease.
about
Persistent high burden of invasive pneumococcal disease in South African HIV-infected adults in the era of an antiretroviral treatment programEpidemiology, diagnosis, and antimicrobial treatment of acute bacterial meningitis.Tuberculosis and pneumonia in HIV-infected children: an overviewGuidance on vaccination of HIV-infected children in Europe.Associations between potential bacterial pathogens in the nasopharynx of HIV infected children.Serotype distribution and antibiotic susceptibility of Streptococcus pneumoniae strains carried by children infected with human immunodeficiency virus.B cells in HIV infection and diseaseImmunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in HIV-infected individuals naive to pneumococcal vaccination.Immunogenicity of the Bivalent Oral Cholera Vaccine Shanchol in Haitian Adults With HIV InfectionSafety, immunogenicity and efficacy of pneumococcal conjugate vaccine in HIV-infected individuals.Bacterial meningitis and Haemophilus influenzae type b conjugate vaccine, Malawi.Acute exercise enhancement of pneumococcal vaccination response: a randomised controlled trial of weaker and stronger immune responseUnderstanding the contribution of common childhood illnesses and opportunistic infections to morbidity and mortality in children living with HIV in resource-limited settings.Risk factors of severe pneumonia among children aged 2-59 months in western Kenya: a case control study.Role of IL-21 and IL-21 receptor on B cells in HIV infection.Risk factors for death and severe sequelae in Malawian children with bacterial meningitis, 1997-2010.Bloodstream infections in HIV-infected patients.Pathogenic mechanisms of B-lymphocyte dysfunction in HIV diseaseAntibody persistence and immunologic memory after sequential pneumococcal conjugate and polysaccharide vaccination in HIV-infected children on highly active antiretroviral therapy.Serologic response to primary vaccination with 7-valent pneumococcal conjugate vaccine is better than with 23-valent pneumococcal polysaccharide vaccine in HIV-infected patients in the era of combination antiretroviral therapy.Management of community-acquired pneumonia in HIV-infected children.10-valent pneumococcal nontypeable Haemophilus influenzae PD conjugate vaccine: Synflorix.Maternal pneumococcal capsular IgG antibodies and transplacental transfer are low in South Asian HIV-infected mother-infant pairs.Use of the 13-valent pneumococcal conjugate vaccine in children and adolescents aged 6 - 17 years.Pneumococcal immunization in immunocompromised hosts: where do we stand?Survival of HIV-1 vertically infected children.Epidemiology of invasive pneumococcal disease and vaccine provision in a tertiary referral center.Immunogenicity and Safety of 13-Valent Pneumococcal Conjugate Vaccine in HIV-Infected Adults Previously Vaccinated With Pneumococcal Polysaccharide Vaccine.Dynamics of nasopharyngeal bacterial colonisation in HIV-exposed young infants in Tanzania.Clinical Outcomes and Hospitalizations among Children Perinatally Infected with HIV-1 in Baja California, Mexico.Nasopharyngeal carriage of Streptococcus pneumoniae among HIV-infected and -uninfected children <5 years of age before introduction of pneumococcal conjugate vaccine in Mozambique.
P2860
Q28742203-0B3CAA8B-A577-45EC-9E60-7BAE4E4DAE74Q30431534-E404DD23-E123-4C43-9944-2522CCA88E18Q33801297-9C09F92C-E1FD-4E8A-A96D-4FEA02A1E317Q34251138-CF08A5D0-D7A0-4E14-9258-5D909C93B61DQ34262780-F7935DAD-BDEA-4E5F-A3B7-5F863D4F7DD7Q34400566-12E2E00D-2A08-49CE-A7B0-8DC648513ACEQ34605780-C492255B-5B90-43F7-88EE-4E32DC0E38C8Q35907519-EC839012-D13A-4A39-8DD2-C1F0A613AE4BQ35965212-A79A682F-CA3D-4048-88F9-89E0AE1F2ADEQ36009704-BFFD4EC3-CC1B-40F8-BEAE-7EEF155AADE3Q36039563-8DF1A0C5-192A-4C8D-BFF4-6AA8727B5BA7Q36275718-F712AD9A-8B56-4454-B936-B85F837C741DQ36288227-84A76BF1-8E39-42B3-BB7C-64DC18E10119Q36525608-B4A7241F-E1E7-429A-BEAB-9349CB57C35BQ36670538-5D6523EA-FFBA-4291-A519-C962513731BEQ36900972-653FF187-1C9C-4570-B7D2-60DF3A993488Q36913307-808E134B-7D66-4B91-AC42-AF4705AE7B74Q37189179-181DBAFB-7A76-479D-B479-D8CAC7952C61Q37302272-9A7862D8-1122-44F6-834E-D5DB42FE6F36Q37384771-BB5DA8E9-9CA0-4466-8E92-F141B456AE04Q37463218-98EB9F0C-4CF9-49A4-A974-44071C0E37F1Q37622887-A5759BF2-E445-4CDE-BDD0-F9A50FAE2CAFQ37683620-262C9B27-D3A0-491E-8301-B3A83C59F515Q38124392-01D5CA53-B840-40C4-87D1-0E38B6C7235DQ38168902-6C62E81B-B365-4E44-A0C2-EFBA7A0F474DQ38975088-72825F38-B6A5-436A-B950-C7835487E1D0Q39446045-816BED31-CE79-4AB1-858D-D34D31A1DFEEQ41662682-17AE34D1-3C11-424E-908C-C96ECD0C1B75Q42278710-853DD91E-29B5-4184-9855-E7C849218B8CQ46948089-05B3C0D6-11EB-4B95-AD98-BF8AD7D7F5BBQ49980280-2B50D324-531B-4435-8BA4-CF6826D568F9
P2860
The evidence for using conjugate vaccines to protect HIV-infected children against pneumococcal disease.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
The evidence for using conjuga ...... against pneumococcal disease.
@en
type
label
The evidence for using conjuga ...... against pneumococcal disease.
@en
prefLabel
The evidence for using conjuga ...... against pneumococcal disease.
@en
P2093
P1476
The evidence for using conjuga ...... against pneumococcal disease.
@en
P2093
Edward N Janoff
Mark F Cotton
Orin S Levine
Philippa Musoke
Sandra J Bliss
P356
10.1016/S1473-3099(07)70242-6
P577
2007-10-31T00:00:00Z